The latest Cancer Risk Survey: Breast Cancer Edition shows that more than half (63%) of women do not know that breast density is associated with an increased risk of breast cancer.  

Though dense breast tissue is normal, women who have it are at a slightly elevated risk for developing breast cancer. New FDA guidelines require that all breast imaging facilities must alert patients by letter if they have dense breasts, and provide recommendations that they contact their care provider for follow-up and risk assessment.  

For women with dense breasts, additional screening methods such as ultrasound or MRI may be recommended together with mammography to improve cancer detection rates. 

“Dense breasts present unique challenges in breast cancer screening, but awareness and proactive management can help mitigate these challenges,” said Dr. Ifeyinwa Stitt, an OB-GYN physician and Myriad speaker practicing in Maryland. “By understanding their breast density and cancer risk, women can make informed decisions about their screening options and take proactive steps to prioritize their well-being.”  

The survey also revealed that though the majority (92%) of women understand detecting cancer early means they have more treatment options, which means a higher chance for better outcomes, only 66% of women believe annual breast checks are necessary.  

40% of women, if identified as having dense breasts, think they should receive additional screenings like MRIs or ultrasounds; only 1/3 of those would consider genetic testing.  

These findings expose a critical gap in understanding, as genetic testing may reveal patients at increased risk that would benefit from additional screenings that could identify cancer at its earliest, most treatable stage. By combining genetic insights, family history and other clinical factors like breast density, MyRisk^® Hereditary Cancer Test with RiskScore^® calculates a woman’s 5-year and remaining lifetime risk of breast cancer. If a woman is found to be at high risk, she then has multiple options available to her, including a change in medical management.    

 
“Breast cancer has impacted my family since before I was born – my great grandmother, grandmother and mother all passed away from breast cancer. My mother lost her battle at only 42, when I was only 21-years old,” said Ashley Dedmon, a patient advocate for Myriad’s MyRisk with RiskScore test. “I want every clinician in the country who may not think genetic testing is necessary to hear my story. Your patients want and need this screening.”  

Go to Get MyRisk to learn more.